Novartis/Schering AG Re-Evaluating PTK/ZK Due To Low Probability Of Survival Benefit
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis and Schering AG plan to re-evaluate their development strategy for PTK/ZK 787 (vatalanib) following an interim analysis showing a low probability of a survival benefit in the second-line metastatic colorectal cancer setting